Furthermore, the central role of PARP1 and PHB2 in the MCC interaction network of human MM cells implies that PARP1 inhibitors and PHB ligands may have therapeutic application in B cell neoplasms, including NHL and MM. This evidence concerns the gene PHB1 and non-Hodgkin lymphoma.